Pertuzumab Perjeta News Today : Breaking News, Live Updates & Top Stories | Vimarsana

email article Neoadjuvant chemotherapy is the treatment of choice for newly diagnosed inflammatory or unresectable breast cancer, as well as locally advanced disease that might be rendered operable with neoadjuvant therapy, according to a new guideline from the American Society of Clinical Oncology (ASCO). A limited number of factors have sufficient evidence to support routine use of clinical decision-making: tumor histology, grade, stage, and hormone receptor (HR) status (estrogen, progesterone, and HER2). Data remain insufficient to support use of other markers or genomic profiling to inform decisions about neoadjuvant chemotherapy, stated guideline panel co-chairs Larissa A. Korde, MD, of the National Cancer Institute in Bethesda, Maryland, and Dawn L. Hershman, MD, of Columbia University in New York City, and co-authors in the

New yorkUnited statesColumbia universityCharles bankheadPertuzumab perjetaLarissaa kordeNational cancer institute in bethesdaAmerican society of clinical oncologyAmerican societyClinical oncologyNational cancer instituteNew york cityMedpage todayCarcinoma of breastMalignant tumor of breastNeoplastic disease